Jair Soares
Psychiatry · San Antonio, TXNPI 1871501072
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $54,240 of the $69,455 with a category attached, or 78.1%. 15 manufacturers reported payments, led by Alkermes, Inc. at 58.5% of the total. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 78 payments — averaging $890.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$41K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$9K
- Merck$8K
- Johnson & Johnson$5K
- Livanova USA, Inc.$3K
- Boehringer Ingelheim$1K
- plus $2K from 9 others
Across 61 payments — averaging $1233.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sumitomo Pharma America, Inc.$44K
- Alkermes, Inc.$25K
- AbbVie$4K
- Sunovion Pharmaceuticals Inc.$1K
- Pfizer$450
What the payments were for
- Consulting fees$54,24078%
- Speaking & faculty fees$8,40012%
- Travel & lodging$3,4975%
- Food & beverage$3,3015%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 16 | $40,644 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 8 | $8,517 |
| Merck | 10 | $8,251 |
| Johnson & Johnson | 9 | $5,431 |
| Livanova USA, Inc. | 9 | $3,462 |
| Boehringer Ingelheim | 2 | $1,395 |
| AbbVie(2 entities) | 10 | $796 |
| Janssen Scientific Affairs, LLC | 4 | $358 |
| Supernus Pharmaceuticals, Inc. | 2 | $176 |
| Axsome Therapeutics, Inc. | 1 | $99 |
| Sunovion Pharmaceuticals Inc. | 1 | $93 |
| E.r. Squibb & Sons, L.L.C. | 2 | $88 |
| Biogen | 2 | $67 |
| Neurocrine Biosciences, Inc. | 1 | $39 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $38 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$5,453
- LYBALVI$4,200
- VNS Therapy$3,004
- REJOYN$1,500
- VRAYLAR$354
- VNS Therapy Symmetry Model 8103 Generator$215
- QELBREE$122
- INVEGA SUSTENNA$121
- VNS - Symmetry$108
How this compares
$69,455 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clonazepam | 24 | $350 |
| Sertraline Hcl | 12 | $109 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in San Antonio
- Thomas WeissSan Antonio$744K
- Nathan JohnstonSan Antonio$435K
- Damaso OlivaSan Antonio$170K
- Edmund WilliamsSan Antonio$142K
- James RedmondSan Antonio$42K
- Rakesh JainLake Jackson$7.2M
- Arvinder Pal WaliaAustin$2.5M
- Suresh SureddiPlano$2.2M
- Martin GuerreroEl Paso$2M
- Marty BennettAddison$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.